Kalvista Pharm Stock Price, News & Analysis

KalVista Pharmaceuticals (NASDAQ: KALV) has announced plans to offer $110.0 million in Convertible Senior Notes due 2031 through a private placement to qualified institutional buyers. The company will grant initial purchasers an option for an additional $15.0 million in notes. The notes will be senior, unsecured obligations with semi-annual interest payments.

The notes will mature on October 1, 2031, with conversion options available under specific conditions. KalVista can settle conversions in common stock, cash, or a combination thereof. The company plans to use the proceeds for working capital, general corporate purposes, and the commercialization of EKTERLY, with potential allocation for future investments and acquisitions.

KalVista Pharmaceuticals (NASDAQ:KALV) has received approval from both the European Commission and Swissmedic for EKTERLY® (sebetralstat), marking a significant milestone as the first and only oral on-demand treatment for hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older.

The approval is based on the phase 3 KONFIDENT trial, the largest HAE clinical study to date, which demonstrated EKTERLY's superior efficacy over placebo in providing faster symptom relief and attack resolution. The trial involved 136 HAE patients across 66 clinical sites in 20 countries.

KalVista plans to launch EKTERLY first in Germany in Q4 2025, followed by Switzerland in H2 2026. The EC approval covers all 27 EU member states plus Iceland, Liechtenstein, and Norway, with 10 years of market exclusivity granted through orphan designation.

KalVista Pharmaceuticals (NASDAQ:KALV) reported significant progress in Q1 fiscal 2025, highlighted by the FDA approval and launch of EKTERLY®, the first oral on-demand treatment for hereditary angioedema (HAE). The company received 460 patient start forms in just eight weeks post-launch, representing nearly 5% of the US HAE patient population.

The company achieved $1.4 million in net product revenue following EKTERLY's mid-July launch. KalVista secured UK approval and received a positive CHMP opinion recommending EU approval, with a final decision expected in October 2025. The company maintains a strong financial position with $191.5 million in cash, providing runway into 2027.

KalVista Pharmaceuticals (NASDAQ:KALV) has scheduled a live webcast for September 11, 2025, at 8:30 a.m. ET to provide an operational update and release its financial results for the fiscal quarter ended July 31, 2025. Investors can access the webcast through the Investors section of KalVista.com. A replay of the presentation will remain available for at least 30 days after the event.

KalVista Pharmaceuticals (NASDAQ:KALV) announced the granting of inducement stock options to two new employees. The compensation committee approved options to purchase a total of 5,000 shares of KalVista common stock on September 1, 2025.

The options will vest over a four-year period, with 25% vesting after the first year and the remainder vesting monthly over the following three years. The options have a 10-year term and an exercise price equal to the closing price of KalVista stock on the first day following the grant date. These grants were made under KalVista's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

KalVista Pharmaceuticals (NASDAQ:KALV) announced its upcoming participation in the Cantor Global Healthcare Conference 2025. The company will engage in a fireside chat on Wednesday, September 3, 2025, at 10:55 a.m. ET.

Investors can access a live webcast of the presentation through KalVista's website at www.kalvista.com. The audio recording will remain available on the company's website for 30 days following the presentation.

KalVista Pharmaceuticals (NASDAQ:KALV) announced that sebetralstat, its novel oral plasma kallikrein inhibitor for hereditary angioedema (HAE), has maintained its orphan drug designation from the European Medicines Agency (EMA). This achievement makes sebetralstat one of only two HAE therapies to maintain orphan status in the EU.

The designation was maintained based on sebetralstat's comparable efficacy to injectable treatments while offering significant benefits to patient care. If approved, the drug will receive 10 years of market exclusivity in the EU. The European Commission's final decision is expected by early October 2025, following a positive CHMP opinion.

KalVista Pharmaceuticals (NASDAQ:KALV) announced the granting of inducement stock options to six newly-hired employees. The compensation committee approved options to purchase a total of 44,000 shares of KalVista common stock on August 1, 2025.

The options will vest over a four-year period, with 25% vesting after one year and the remainder vesting monthly over the following three years. The exercise price equals the closing price on the grant date, and the options have a 10-year term. These grants were made under KalVista's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

KalVista Pharmaceuticals (NASDAQ:KALV) has received a positive opinion from the European Medicines Agency's CHMP recommending marketing authorization for sebetralstat, their novel oral plasma kallikrein inhibitor for treating hereditary angioedema (HAE) attacks. The treatment, if approved, will become the first and only oral on-demand treatment for HAE in the EU.

The recommendation is based on the phase 3 KONFIDENT trial, the largest HAE clinical trial to date, involving 136 patients across 66 sites in 20 countries. The trial demonstrated significantly faster symptom relief and attack resolution compared to placebo. The European Commission's final decision is expected by early October 2025. Sebetralstat is already approved in the US and UK under the brand name EKTERLY® and is under review in Japan and other territories.